Responses To Romidepsin In Patients With Cutaneous T-Cell Lymphoma (Ctcl) With Tumors And/Or Folliculotropic Involvement.

8575 Background: CTCL is a heterogeneous group of non-Hodgkin lymphomas that arises in the skin (patches, plaques, tumors, and/or erythroderma) but can involve the lymph, blood, and/or viscera. Additionally, patients with cutaneous tumors or folliculotropic involvement typically have poor prognoses. Romidepsin is a histone deacetylase inhibitor approved by the US FDA for the treatment of patients with CTCL who have received ≥ 1 prior systemic therapy. Durable responses (objective response rate [ORR; complete [CR] + partial responses] of 34% and median duration of response of 15 mo) and tolerability with extended dosing have been reported. To examine responses to romidepsin in these less favorable prognostic subsets, patients with tumors or folliculotropic involvement in the pivotal study of romidepsin for the treatment of CTCL were analyzed. Methods: Patients with CTCL (N = 96) who had ≥ 1 prior systemic therapy received romidepsin 14 mg/m2on days 1, 8, and 15 every 28 days. Responses were determined by a...